Eli Lilly and Company is a global pharmaceutical corporation that specializes in the discovery, development, manufacturing, and distribution of medicines. Its portfolio spans various therapeutic areas, including neuroscience, cardiometabolic, cancer, and immunology. Notable products include Verzenio for cancer, Mounjaro and Jardiance for cardiometabolic conditions, and Taltz for immunology. The company operates through owned or leased facilities in over 25 countries, selling its products in approximately 135 countries worldwide. Additionally, Eli Lilly and Company Foundation, established in 1968, supports initiatives aimed at improving patient outcomes, enhancing quality of life, and promoting education, particularly in underserved communities.
Group Vice President - Molecule Discovery and Director, Lilly Institutes of Genetic Medicine
Anat Ashkenazi
CFO
Gordon Brooks
Group Vice President - Controller and Corporate Strategy
Lotus Mallbris Ph.D
Vice President of Development and Immunology
Teresa Millan
Corporate Affairs Director
Jacob Van Naarden
President
Diogo Rau
Executive Vice President and Chief Information and Digital Officer
Melissa Seymour
Executive VP of Global Quality
Past deals in Medical
Grove Biopharma
Series A in 2025
Grove Biopharma is a biotechnology company dedicated to addressing unmet medical needs in oncology, chronic inflammatory, and neurodegenerative diseases. It specializes in the discovery and development of a new class of protein-like polymers, utilizing artificial intelligence and precision polymer chemistry to create hybrid synthetic protein mimetics. The company also provides materials science solutions to tackle challenges associated with peptide therapeutics, thereby facilitating researchers' access to innovative drugs in critical areas of healthcare.
Solu Therapeutics
Series A in 2025
Solu Therapeutics is a precision medicine company dedicated to developing innovative therapeutics aimed at eliminating cells responsible for driving diseases. Utilizing a unique cytotoxicity-targeting chimera platform, Solu Therapeutics focuses on oncology and also addresses inflammatory and autoimmune diseases. By targeting these disease-driving cells, the company's approach seeks to assist medical professionals in reducing the risks associated with various oncological conditions, ultimately improving patient outcomes and advancing therapeutic options in the healthcare sector.
Augustine Therapeutics
Series A in 2025
Augustine Therapeutics N.V., founded in 2019 and based in Gent, Belgium, focuses on developing innovative medicines for patients suffering from Charcot-Marie-Tooth disease and other neuromuscular disorders. The company is engaged in two drug discovery programs aimed at identifying new generations of selective HDAC6 inhibitors, which are designed to address axonopathies, including Charcot-Marie-Tooth disease. These novel compounds are intended to protect against nerve degeneration and facilitate the repair of peripheral myelin and axons. By advancing these therapeutic drugs, Augustine Therapeutics aims to enhance the quality of life for patients affected by these debilitating conditions.
Ampersand Biomedicines
Series B in 2025
Ampersand Biomedicines is a biopharmaceutical company that focuses on developing innovative programming therapeutics aimed at targeting diseases directly at their site of occurrence. The company employs its Address, Navigate, Design (AND)™ Platform to create localized treatments that enhance precision in disease management. By integrating a localizing element with a carefully selected actuator for disease modification, Ampersand Biomedicines enables researchers to address a broad spectrum of diseases across various body systems. This approach allows for a tailored therapeutic response, potentially improving the efficacy of treatments and advancing the field of precision medicine.
Maxion Therapeutics
Series A in 2025
Maxion Therapeutics specializes in developing innovative therapies through its drug discovery platform, which focuses on creating antibody-like therapeutics targeting ion channel and GPCR-driven diseases. The company utilizes unique ion channel-modulating mini-proteins, known as knottins, derived from venom and other sources, integrating them with antibody frameworks. This approach preserves the functional properties of knottins while enhancing the drug-like characteristics typical of antibodies. By doing so, Maxion Therapeutics aims to provide long-acting, safe, and effective treatments for conditions such as chronic pain, autoimmune disorders, and heart disease, addressing previously inaccessible therapeutic targets.
Insilico Medicine
Series E in 2025
Insilico Medicine, Inc. is a biotechnology company that utilizes artificial intelligence to advance drug discovery, biomarker development, and research into aging. Founded in 2014 and based in Baltimore, Maryland, the company has developed a comprehensive AI platform that employs techniques such as generative adversarial networks and reinforcement learning to create novel molecular structures aimed at treating cancer and age-related diseases. Insilico Medicine operates various projects, including Pharma.AI, which offers machine learning services to biotechnology and pharmaceutical companies, and Young.AI, which predicts biological age. The company is actively engaged in internal drug discovery efforts targeting conditions like Alzheimer's disease, Parkinson's disease, and diabetes, and has partnered with Life Extension to produce nutraceutical products using advanced bioinformatics. Additionally, Insilico Medicine provides consumer applications and services to academic institutions and the cosmetic industry, solidifying its role in the intersection of AI and healthcare.
Scorpion Therapeutics
Acquisition in 2025
Scorpion Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing next-generation precision oncology technologies for cancer treatment. Founded in 2020, the company specializes in creating targeted small-molecule drugs that interact with validated cancer targets. Its research encompasses therapies aimed at known oncogenes, previously undruggable cancer targets, and novel targets. By integrating technologies across target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics aims to advance a comprehensive pipeline of optimized compounds. The company's goal is to expand the reach of precision medicine, enabling healthcare professionals to offer innovative treatments to a broader range of cancer patients.
Orbis Medicines
Series A in 2025
Orbis Medicines is a company focused on drug discovery, utilizing a unique macrocyclic chemistry and computational platform to develop new therapeutics. By employing high-throughput techniques, Orbis aims to accelerate the drug discovery process, particularly for challenging targets that address significant unmet medical needs. Their innovative approach is designed to enhance the efficiency and effectiveness of developing treatments, ultimately improving patient outcomes.
Revisto
Seed Round in 2024
Revisto is a technology company that specializes in streamlining the medical, legal, and regulatory review process for pharmaceutical marketing materials. Utilizing AI, their platform accelerates the release time of these materials, reduces costs, and mitigates compliance risks. It automates the review process, provides content recommendations based on historical data, and ensures adherence to regulatory requirements.
Sunbird Bio
Venture Round in 2024
Sunbird Bio is a diagnostics platform developer focused on advancing molecular diagnostics to deliver faster and more accurate results. Founded by Huilin Shao, the company specializes in detecting a wide array of diseases, including infectious diseases, neurodegenerative disorders, and cancer. By enabling early diagnosis, Sunbird Bio aims to enhance healthcare outcomes and support physicians in making informed decisions. The platform is designed to improve clarity and accessibility in diagnostic testing, thereby contributing to better patient care.
Arda Therapeutics
Series A in 2024
Arda Therapeutics is a biotechnology company founded in 2021 in the San Francisco Bay Area that focuses on addressing chronic diseases and aging by targeting and eliminating pathogenic cells responsible for these conditions. The company utilizes single-cell data to identify specific pathogenic cells and their markers, allowing for the development of precise therapies that exclusively eliminate these harmful cells. This targeted approach aims to eradicate the entire pathological network while preserving healthy cells, thereby enabling effective treatment without adverse effects on the patient's overall cellular health.
Amprion
Series B in 2024
Amprion is a biotechnology company based in San Francisco, California, established in 2007. The firm specializes in the diagnosis of neurodegenerative diseases, particularly focusing on conditions such as Parkinson’s disease, Alzheimer’s disease, and Lewy Body Dementia. Amprion develops innovative early detection technologies aimed at improving understanding of brain health. By leveraging personal biometrics and collective knowledge, the company seeks to enhance the ability of researchers and healthcare professionals to identify and understand these brain diseases, ultimately contributing to better patient outcomes and advancing the field of neuroscience.
NanoSyrinx
Series A in 2024
NanoSyrinx is a biotechnology company focused on developing an innovative system for the targeted delivery of therapeutic proteins and peptides directly into the cytosol of cells. By employing synthetic biology techniques, the company aims to create a groundbreaking method for drug delivery that enhances the efficacy, safety, and cost-effectiveness of treatments in the biopharmaceutical sector. This novel approach allows for precise delivery of therapeutic agents, potentially improving treatment outcomes for patients by ensuring that the drugs reach their intended cellular targets.
Superluminal Medicines
Series A in 2024
Superluminal Medicines is a biotechnology company specializing in generative biology and chemistry. It employs a unique platform that combines deep biological and chemical expertise, machine learning, and proprietary big data infrastructure to rapidly generate candidate-ready compounds for drug discovery and development. By integrating high-throughput experimental data with advanced algorithms, the company aims to accelerate the identification and optimization of novel drug candidates, improving efficiency and success rates in small molecule drug development compared to traditional methods.
OrsoBio
Series B in 2024
OrsoBio is a clinical-stage biopharmaceutical company focused on developing therapies for severe metabolic disorders, including obesity and related conditions such as type 2 diabetes and severe dyslipidemia. The company aims to restore energy homeostasis in patients by targeting pathways that maintain energy balance, thereby addressing the underlying causes of these disorders. OrsoBio's commitment to innovation seeks to revolutionize treatment options for individuals suffering from metabolic dysfunctions, including lipodystrophies and other obesity-associated complications. Through its research and development efforts, OrsoBio strives to enhance patients' energy metabolism and improve their overall health outcomes.
Circle Pharma
Series D in 2024
Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, founded in 2012 by Matt Jacobson and Scott Lokey. The company focuses on developing cell-permeable macrocyclic peptide therapeutics by employing proprietary computational design algorithms and innovative synthetic chemistry. Circle Pharma utilizes an iterative design process that leverages large virtual libraries of conformationally diverse macrocycle scaffolds, which are selected for their inherent permeability. This approach allows the company to create first-in-class macrocycle therapies that can be administered through multiple routes, including oral delivery. The therapeutics target challenging clinical issues, particularly intracellular protein-protein interactions that are significant contributors to cancer, thereby addressing unmet medical needs and enhancing the capabilities of healthcare professionals in their treatment efforts.
RetiSpec
Series A in 2024
RetiSpec is focused on creating a non-invasive eye scanner designed for the early detection of Alzheimer's Disease pathology, potentially years before symptoms manifest. By employing AI-driven retinal imaging technology, RetiSpec's approach allows for a straightforward eye exam that identifies markers of neurodegenerative diseases. This innovation aims to provide healthcare providers with a means to deliver accessible, affordable, and scalable early diagnosis, facilitating timely interventions with emerging therapeutics that can significantly impact the progression of the disease.
Circle Pharma
Series D in 2024
Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, founded in 2012 by Matt Jacobson and Scott Lokey. The company focuses on developing cell-permeable macrocyclic peptide therapeutics by employing proprietary computational design algorithms and innovative synthetic chemistry. Circle Pharma utilizes an iterative design process that leverages large virtual libraries of conformationally diverse macrocycle scaffolds, which are selected for their inherent permeability. This approach allows the company to create first-in-class macrocycle therapies that can be administered through multiple routes, including oral delivery. The therapeutics target challenging clinical issues, particularly intracellular protein-protein interactions that are significant contributors to cancer, thereby addressing unmet medical needs and enhancing the capabilities of healthcare professionals in their treatment efforts.
Augustine Therapeutics
Series A in 2024
Augustine Therapeutics N.V., founded in 2019 and based in Gent, Belgium, focuses on developing innovative medicines for patients suffering from Charcot-Marie-Tooth disease and other neuromuscular disorders. The company is engaged in two drug discovery programs aimed at identifying new generations of selective HDAC6 inhibitors, which are designed to address axonopathies, including Charcot-Marie-Tooth disease. These novel compounds are intended to protect against nerve degeneration and facilitate the repair of peripheral myelin and axons. By advancing these therapeutic drugs, Augustine Therapeutics aims to enhance the quality of life for patients affected by these debilitating conditions.
Radar Therapeutics
Seed Round in 2024
Radar Therapeutics specializes in developing innovative, mRNA-based therapeutics that target and treat diseases by recognizing and responding to specific transcriptional signatures in pathogenic cells. Their proprietary technology enables precise, programmable therapies, expanding treatment possibilities to previously undruggable targets.
Ajax Therapeutics
Series C in 2024
Ajax Therapeutics is a biotechnology company based in New York City that focuses on developing innovative small molecule therapies for hematologic malignancies. The company utilizes computational chemistry and structure-based technologies to create targeted treatments that address critical cytokine signaling pathways involved in these diseases. By integrating insights from disease mechanisms, genetics, and structural biology with an advanced computational drug discovery platform, Ajax Therapeutics aims to design precise therapeutics that meet significant unmet medical needs for patients suffering from hematologic malignancies.
FireFly Bio
Series A in 2024
FireFly Bio focuses on developing Degrader Antibody Conjugates (DACs), a novel approach that merges the benefits of antibody-drug conjugates with selective protein degraders. This proprietary healthcare platform is designed to enhance cancer treatment by ensuring the precise delivery of therapeutic agents to targeted tissues. By leveraging advanced bioconjugate technologies, FireFly Bio aims to create more effective and targeted medicines that improve patient outcomes in the fight against cancer.
UpDoc
Seed Round in 2024
UpDoc is a technology-enabled services firm that offers the world's first unique conversational AI platform for autonomous prescription management.
Point Biopharma Global
Acquisition in 2023
Point Biopharma Global Inc., established in 2019 and headquartered in Toronto, Canada, specializes in the development and commercialization of radioligand therapies for cancer treatment. The company leverages a portfolio of advanced radiopharmaceutical assets, expertise in radioisotopes like Actinium-225 and Lutetium-177, and innovative manufacturing technology. Point Biopharma Global's pipeline includes several promising candidates, such as PNT2002, PNT2004, PNT2003, and PNT2001, aiming to revolutionize theragnostic drug development and radioligand commercialization.
Alto Neuroscience
Series C in 2023
Alto Neuroscience is a clinical-stage biopharmaceutical company focused on improving mental health treatment through personalized medicine. By utilizing an AI-enabled biomarker platform, Alto integrates detailed patient data regarding brain activity and behavior to develop effective therapeutics for specific populations. The company aims to transform the traditional trial-and-error approach in psychiatry by matching the appropriate treatment to individual patients, thereby enhancing the effectiveness of interventions. Alto's clinical-stage assets include various products targeting conditions such as depressive disorders and schizophrenia, identified through independent brain-based biomarkers. Through its innovative approach, Alto Neuroscience seeks to redefine psychiatric care at a critical time for mental health.
ViaNautis
Series A in 2023
ViaNautis is focused on creating innovative medications that can effectively cross biological barriers, particularly the blood-brain barrier (BBB). The company utilizes PolyNaut, a versatile nano-engineered polymer technology, to enhance intracellular delivery of therapeutics. Through the development of nanoparticle technology, ViaNautis encapsulates various therapeutic modalities within polymer nanovesicles, allowing for selective targeting of different tissues and cell types. This approach significantly improves the therapeutic efficacy of the delivered molecules, enabling clients to achieve better treatment outcomes. With partners like SomaServe, ViaNautis is paving the way for advanced medications that offer substantial therapeutic benefits by overcoming various biological barriers.
OrsoBio
Series A in 2023
OrsoBio is a clinical-stage biopharmaceutical company focused on developing therapies for severe metabolic disorders, including obesity and related conditions such as type 2 diabetes and severe dyslipidemia. The company aims to restore energy homeostasis in patients by targeting pathways that maintain energy balance, thereby addressing the underlying causes of these disorders. OrsoBio's commitment to innovation seeks to revolutionize treatment options for individuals suffering from metabolic dysfunctions, including lipodystrophies and other obesity-associated complications. Through its research and development efforts, OrsoBio strives to enhance patients' energy metabolism and improve their overall health outcomes.
Laverock Therapeutics
Seed Round in 2023
Laverock Therapeutics is focused on advancing gene silencing technology to create innovative programmable cell therapies. Their platform enables the engineering of next-generation allogeneic cell therapies that can adapt to both internal and external environmental signals. This capability allows for the development of induced pluripotent stem cell (iPSC)-derived products that offer enhanced efficacy, safety, and accessibility, addressing many of the challenges faced by traditional therapeutic methods. Through its pioneering approach, Laverock Therapeutics aims to facilitate significant advancements in the fields of medicine and biotechnology.
Mariana Oncology
Series B in 2023
Mariana Oncology is a biotechnology company focused on developing radiopharmaceuticals designed to target cancer cells using radioactive drugs. The company leverages expertise in ligand discovery, radiochemistry, and radiobiology, along with oncology translational and clinical research, to create a diverse pipeline aimed at treating various solid tumor types. By advancing the use of radiomedicines, Mariana Oncology seeks to enhance treatment options for medical professionals in their fight against cancer.
Amber Bio
Seed Round in 2023
Amber Bio is a biotechnology company pioneering new gene editing modalities using multi-kilobase edits to reach previously undruggable patient populations.
Versanis Bio
Acquisition in 2023
Versanis Bio is focused on discovering and developing medicines that target medical conditions commonly found in older adults. The company is advancing Bimagrumab, a human monoclonal antibody that inhibits activin type II receptors, blocking the action of ligands such as activin A and myostatin. Previous studies conducted by Novartis involved over 1,500 participants and demonstrated that Bimagrumab consistently induced significant fat loss while preserving lean mass. Additionally, the treatment has shown improvements in HbA1c levels and other cardiometabolic parameters, offering a promising option for overweight and obese adults aiming to achieve and maintain a healthier body composition.
Crossbow Therapeutics
Series A in 2023
Crossbow Therapeutics is a biotechnology company focused on developing innovative cancer treatments. The company engineers antibodies that mimic T-cells, which are essential components of the immune system, to target cancer cells with high precision. This next-generation approach allows for the assembly of immunotherapies that can reach previously inaccessible cancer cell targets, significantly broadening the scope of antibody therapy. By utilizing T-cell receptor (TCR)-mimetic antibodies, Crossbow Therapeutics aims to enhance the quality of life for cancer patients and unlock new therapeutic potentials across various types of cancer.
Emergence Therapeutics
Acquisition in 2023
Emergence Therapeutics AG is a biopharmaceutical company based in Duisburg, Germany, focused on developing novel antibody-drug conjugate (ADC) immuno-therapeutics for high-need cancers. Founded in 2019, the company is advancing its lead program, which combines a highly specific antibody with optimized linker and payload technology to target Nectin-4, a clinically validated target for various cancers. This approach is inspired by the success of enfortumab vedotin, an approved treatment for urothelial cancers. Emergence Therapeutics is also exploring opportunities to create additional first- or best-in-class ADCs, aiming to address significant therapeutic needs in oncology.
DICE Therapeutics
Acquisition in 2023
DICE Therapeutics is a biopharmaceutical company that utilizes its proprietary technology platform to develop a pipeline of novel oral therapeutic candidates aimed at treating chronic diseases, particularly in the field of immunology. The company focuses on creating oral therapeutics that target well-established proteins, intending to achieve efficacy similar to existing systemic biologics. DICE's DELSCAPE platform is specifically designed to discover selective oral small molecules capable of modulating protein-protein interactions effectively. Its lead candidate, S011806, is an oral antagonist targeting interleukin-17, a key player in various immunological conditions. In addition to S011806, DICE is developing other oral therapeutic candidates that target α4ß7 integrin and αVß1/αVß6 integrin, aimed at treating inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.
Verve Therapeutics
Post in 2023
Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.
Diogenx
Series A in 2023
DiogenX is a preclinical stage biotech company based in Marseille, France, with research labs in Nice. Founded in 2019, the company specializes in developing therapeutic solutions for diabetic patients, focusing on pancreatic beta-cell modulators for the treatment of Type 1 and Type 2 diabetes. DiogenX aims to create a candidate molecule that regenerates insulin-producing pancreatic cells, potentially improving the quality of life and survival rates for individuals with diabetes. The innovative therapy is based on research conducted in the laboratory of Dr. Patrick Collombat, which positions DiogenX as a pioneer in the development of beta-cell regeneration treatments for diabetes.
Therini Bio
Series A in 2023
Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies aimed at treating inflammatory neurological and retinal diseases. The company leverages insights from research that highlights the role of fibrin in driving chronic innate immune activation, which is implicated in various human diseases with significant unmet medical needs. Currently, Therini Bio is working on therapeutics that aim to protect the nervous system from damage associated with conditions such as multiple sclerosis. By developing specialized antibodies for neuroinflammatory diseases linked to vascular dysfunction, the company seeks to provide healthcare providers with effective treatment options that can improve patient outcomes.
Mediar Therapeutics
Series A in 2023
Mediar Therapeutics is a pre-clinical stage biotechnology company based in Cambridge, Massachusetts, focused on developing antibody-based therapeutics for the treatment of fibrosis. Founded in 2019, the company aims to provide innovative solutions by targeting key fibrotic mediator proteins that contribute to the development of fibrosis in chronically damaged organs. Through its research and development efforts, Mediar seeks to enable medical practitioners to halt and potentially reverse critical fibrosis and related conditions, addressing a significant unmet need in the field of fibrotic diseases.
Switch Therapeutics
Series A in 2023
Switch Therapeutics is a biotechnology company established in 2020 and located in San Francisco, California. The company focuses on developing innovative RNA interference (RNAi) therapies aimed at transforming the treatment of various diseases, particularly those affecting the central nervous system and other systemic conditions with significant unmet medical needs. By integrating nucleic acid nanotechnology with RNAi science, Switch Therapeutics creates biomarker-gated genetic medicines designed to activate RNA molecules and therapies specifically in targeted cells. This targeted approach aims to enhance the effectiveness of treatments for central nervous system diseases, providing healthcare providers with advanced therapeutic options.
IgGenix
Series B in 2023
IgGenix, Inc. is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of food and other severe allergies. Founded in 2019 and based in South San Francisco, California, the company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies. This process aims to alleviate and prevent allergic reactions by suppressing the allergic cascade. IgGenix captures and analyzes rare human B cells that produce allergen-binding antibodies and engineers these cells to enhance their immune-modulating properties. By addressing critical needs in the medical industry, IgGenix seeks to provide effective solutions for life-threatening allergic reactions.
SonoThera
Series A in 2022
SonoThera is a biotechnology company focused on developing non-viral genetic therapies using ultrasound technology. The company aims to create genetic medicines that address the root causes of human diseases, particularly for conditions that currently have limited or no effective treatments. By leveraging ultrasound-guided nonviral gene therapy, SonoThera seeks to enhance treatment options and improve health outcomes for millions of patients.
Akouos
Acquisition in 2022
Akouos, Inc. is a biotechnology company based in Boston, Massachusetts, dedicated to developing gene therapies aimed at restoring, improving, and preserving hearing for individuals affected by various inner ear disorders. Founded in 2016, the company utilizes an innovative platform that includes a proprietary adeno-associated viral vector library and a unique delivery method. Its leading product candidate, AK-OTOF, targets hearing loss resulting from mutations in the OTOF gene. Akouos focuses on genetically-defined patient populations, addressing conditions ranging from single genetic mutations to hearing loss caused by ototoxic drugs and aging. The company has established strategic partnerships with key institutions, including Massachusetts Eye and Ear and Lonza, Inc., to advance its mission of providing precision genetic therapies for sensorineural hearing loss.
Capstan Therapeutics
Series A in 2022
Capstan Therapeutics is a biotechnology company focused on enhancing the therapeutic potential of in vivo RNA-based therapies. It develops proprietary targeted delivery systems, including targeted lipid nanoparticles, to improve the efficacy and control of dosage in engineered cell therapies. This innovative platform aims to address a variety of diseases, particularly in the fields of oncology, fibrosis, and inflammation, where there are significant unmet clinical needs. By advancing precision in vivo cell engineering, Capstan Therapeutics seeks to create transformative therapeutics that can offer new solutions for patients facing these challenging conditions.
Photys Therapeutics
Series A in 2022
Photys Therapeutics is a biopharmaceutical company focused on developing bifunctional small molecules that provide precise control over protein post-translational modifications. This innovative platform allows for the restoration of protein function, repair of cellular signaling pathways, and enhancement of the body's natural disease-fighting abilities. Co-founded by prominent chemist Amit Choudhary from the Broad Institute and the Longwood Fund, Photys is supported by a scientific advisory board that includes renowned experts from institutions such as MIT, Salk Institute, and Berkeley. The company's unique approach aims to advance therapeutic options in the healthcare industry, particularly by targeting kinases and potentially phosphatases, to address various diseases effectively.
XellSmart
Series A in 2022
XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.
Arkuda Therapeutics
Series B in 2022
Arkuda Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. The company focuses on developing innovative medicines for patients suffering from neurological diseases, particularly targeting neurodegenerative conditions. Arkuda leverages insights into progranulin and lysosomal biology to create therapies aimed at addressing progranulin deficiency and lysosomal dysfunction, specifically in genetically-defined frontotemporal dementia related to mutations in the GRN gene. Its lead compounds are designed to improve cellular health in the brain, with the goal of delaying disease progression and the onset of symptoms.
Iterative Scopes
Series B in 2022
Iterative Scopes, Inc. is a Boston-based company founded in 2017 that specializes in developing machine learning-powered diagnostic tools aimed at assisting gastroenterologists in the prevention of colon cancer. The company focuses on providing innovative solutions for physicians and the life sciences sector, particularly in the areas of colorectal cancer and inflammatory bowel disease. By leveraging advanced technology, Iterative Scopes aims to enhance diagnostic accuracy and improve patient outcomes in these critical health areas.
Fountain Therapeutics
Series A in 2021
Fountain Therapeutics, Inc. is a biotechnology company focused on developing treatments for age-related diseases. Founded in 2018 and based in San Francisco, California, the company aims to create a future where individuals live healthier for longer. It employs a transformative cellular model that mimics the complex characteristics of aging within a laboratory setting. By integrating this model with advanced artificial intelligence and computer vision, Fountain Therapeutics seeks to establish an innovative platform for identifying novel therapeutic targets. This approach is designed to facilitate the development of effective treatments for diseases associated with aging, ultimately aiming to reverse cellular aging and improve health outcomes.
Mozart Therapeutics
Series A in 2021
Mozart Therapeutics is a biotechnology startup dedicated to developing disease-modifying therapies for autoimmune and inflammatory diseases. The company focuses on a novel regulatory CD8 T cell network to create innovative CD8 Treg modulators aimed at treating a range of autoimmune conditions. By targeting a specific subset of T-lymphocytes, Mozart aims to restore long-term immune balance and prevent the progression of damage caused by autoreactive immune responses. Its pipeline includes first-in-class CD8 Treg modulators designed to delay the onset of autoimmune diseases and improve patient outcomes through advanced treatment options.
Vanqua Bio
Series B in 2021
Vanqua Bio is a biotechnology company dedicated to discovering and developing innovative medicines for patients suffering from neurodegenerative diseases. The company leverages a technology platform that incorporates human genetics and patient-derived neuronal cells to identify and validate new disease pathways linked to lysosomal dysfunction and the inappropriate activation of the innate immune system. Vanqua Bio focuses on creating small-molecule activators of glucocerebrosidase and advancing programs that target the innate immune system, with the aim of addressing the progression of various neurological disorders. Through its efforts, the company seeks to provide healthcare professionals with transformative treatment options for patients facing these challenging conditions.
Iterative Scopes
Series A in 2021
Iterative Scopes, Inc. is a Boston-based company founded in 2017 that specializes in developing machine learning-powered diagnostic tools aimed at assisting gastroenterologists in the prevention of colon cancer. The company focuses on providing innovative solutions for physicians and the life sciences sector, particularly in the areas of colorectal cancer and inflammatory bowel disease. By leveraging advanced technology, Iterative Scopes aims to enhance diagnostic accuracy and improve patient outcomes in these critical health areas.
MiNA Therapeutics
Corporate Round in 2021
MiNA Therapeutics is a clinical-stage biotechnology company based in London, United Kingdom, focused on developing small activating RNA medicines aimed at restoring normal cell function in patients. Established in 2008, the company is advancing its pipeline with products such as MTL-CEBPA combined with Sorafenib for hepatocellular carcinoma and MTL-CEBPA in conjunction with Pembrolizumab for advanced solid tumors. MiNA's innovative approach leverages gene activation mechanisms to transform the treatment landscape for cancer and other serious diseases, enabling healthcare professionals to better address these conditions.
Circle Pharma
Series C in 2021
Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, founded in 2012 by Matt Jacobson and Scott Lokey. The company focuses on developing cell-permeable macrocyclic peptide therapeutics by employing proprietary computational design algorithms and innovative synthetic chemistry. Circle Pharma utilizes an iterative design process that leverages large virtual libraries of conformationally diverse macrocycle scaffolds, which are selected for their inherent permeability. This approach allows the company to create first-in-class macrocycle therapies that can be administered through multiple routes, including oral delivery. The therapeutics target challenging clinical issues, particularly intracellular protein-protein interactions that are significant contributors to cancer, thereby addressing unmet medical needs and enhancing the capabilities of healthcare professionals in their treatment efforts.
Jaguar Gene Therapy
Series B in 2021
Jaguar Gene Therapy is a clinical-stage biotechnology company focused on advancing gene therapy solutions for patients with severe genetic diseases. The company aims to address significant unmet medical needs by developing therapies that target nonworking or absent genes, introducing healthy copies of these genes to restore their function. By accelerating the process of bringing innovative gene therapies from research to clinical application, Jaguar Gene Therapy seeks to improve patient outcomes and enhance the overall standard of care for those affected by genetic disorders.
Amphista Therapeutics
Series B in 2021
Amphista Therapeutics Limited is a biopharmaceutical company based in Motherwell, United Kingdom, established in 2017. The company specializes in targeted protein degradation technology to develop innovative cancer therapeutics. Amphista's approach focuses on harnessing the body's natural processes to selectively and efficiently degrade disease-causing proteins, aiming to create first-in-class treatments. By advancing novel methodologies in targeted protein degradation, Amphista seeks to improve therapeutic efficacy and modulate protein abundance linked to disease progression, ultimately enhancing patient outcomes in oncology.
DTx Pharma
Series B in 2021
DTx Pharma, LLC is a biotechnology company focused on developing and commercializing fatty acid-conjugated peptide therapeutics for patients with rare and chronic diseases. The company specializes in RNA-based therapeutics, utilizing a delivery technology platform that enhances the distribution of nucleic acid drugs to various tissues and organ systems beyond the liver. This innovative approach addresses limitations associated with previous-generation RNA delivery methods, such as poor pharmacokinetics and inadequate cellular uptake. DTx Pharma's products target conditions including retinitis pigmentosa, Duchenne muscular dystrophy, and central nervous system disorders. Founded in 2017 and based in San Diego, California, DTx Pharma aims to provide personalized treatment options across multiple therapeutic areas.
Seraxis
Series C in 2021
Seraxis is a biotechnology company founded in March 2013, with operations in Singapore and the United States, and a GMP lab located in Germantown, Maryland. The company specializes in developing innovative cell and encapsulation technologies aimed at creating a practical cell therapy for insulin-dependent diabetes. Their primary objective is to provide a long-term cure for diabetic patients that eliminates the need for immunosuppression, thereby improving the management of glucose levels through the production of insulin. Seraxis is structured to expedite the development of this therapy while maximizing value for its shareholders.
Blacksmith Medicines
Seed Round in 2021
Blacksmith Medicines is focused on developing innovative therapies that target metal-dependent enzymes, known as metalloenzymes, which play a crucial role in human physiology. With over 30% of known enzymes classified as metalloenzymes, they encompass all major enzyme classes, including oxidoreductases, transferases, and hydrolases. Blacksmith Medicines utilizes a specialized platform that combines a curated library of metal-binding pharmacophores with advanced computational modeling techniques. This approach allows for the rapid and systematic design of small molecule inhibitors that specifically interact with key metal ions within the enzyme's active site. The company's efforts are particularly directed towards creating medicines for immuno-oncology and inflammatory diseases, offering the potential for more effective and selective therapeutic options.
Terns Pharmaceuticals
Series C in 2021
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on discovering and developing molecularly targeted, oral small-molecule drugs aimed at treating cancer and liver diseases. Founded in 2017 and headquartered in Foster City, California, with additional offices in Shanghai, China, Terns is dedicated to advancing a pipeline of innovative therapeutic candidates. Its notable products include TERN-101, a potent farnesoid X receptor agonist, and TERN-201, an amine oxidase inhibitor. The company leverages its expertise in disease biology and medicinal chemistry, along with a capital-efficient drug discovery model and robust clinical development capabilities, to address significant unmet medical needs in both China and the global market.
Faze Medicines
Series A in 2020
Faze Medicines is a biotechnology company founded in 2020 and located in Cambridge, Massachusetts. The company focuses on developing small molecule drugs that target the underlying mechanisms of disease pathology, with initial therapeutic efforts directed towards conditions such as amyotrophic lateral sclerosis (ALS) and myotonic dystrophy type 1 (DM1). Faze Medicines employs advanced screening and proteomics techniques to explore biomolecular condensate interaction networks, which aids in the identification and development of novel therapeutics. Through its innovative approach, Faze aims to provide effective treatments for patients suffering from these challenging diseases.
Disarm Therapeutics
Acquisition in 2020
Disarm Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for patients suffering from neurological diseases. Founded in 2016 and headquartered in Cambridge, Massachusetts, the company aims to create disease-modifying drugs that prevent axonal degeneration, which is a key factor in various neurological disorders. Disarm's portfolio addresses conditions such as multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies, providing potential treatments for acute diseases affecting the central, ocular, and peripheral nervous systems. As of late 2020, Disarm Therapeutics operates as a subsidiary of Eli Lilly and Company.
Nido Biosciences
Venture Round in 2020
Nido Biosciences, Inc., founded in 2018 and based in Boston, Massachusetts, is a clinical-stage company focused on developing precision medicines for severe neurological diseases. The company utilizes a functional genomics discovery platform based on human cell lines to identify novel therapeutic targets, addressing the underlying biology of neurodegenerative diseases. By leveraging advancements in neuroscience and human genetics, Nido aims to create precise medications that restore healthy cell function and improve treatment options for conditions that significantly impact patient quality of life.
Immunocore
Series B in 2020
Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with a focus on discovering and developing novel therapeutics for cancer, viral diseases, and autoimmune conditions. The company specializes in T cell receptor (TCR) technology, which allows it to create innovative bispecific immunotherapies. Its lead product candidate, IMCgp100, is currently undergoing clinical trials for the treatment of metastatic melanoma. Immunocore's proprietary platform enables efficient manufacturing of TCR-based drugs, addressing significant unmet medical needs. Founded in 1999 and previously known as Avidex Limited, Immunocore has expanded its operations with an additional office in Conshohocken.
Dermira
Acquisition in 2020
Dermira, Inc. is a biopharmaceutical company based in Menlo Park, California, that focuses on developing and commercializing therapies for dermatologic conditions in the United States. The company offers QBREXZA, a once-daily topical treatment for primary axillary hyperhidrosis in patients aged nine years and older. Additionally, Dermira is advancing several product candidates, including lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, and glycopyrronium tosylate, which is in Phase III trials for hyperhidrosis. Dermira also has collaborations with other companies for the development and commercialization of its products, such as a partnership with UCB Pharma for Cimzia, aimed at treating chronic plaque psoriasis. Founded in 2010, Dermira aims to provide innovative solutions for dermatologists and their patients.
DTx Pharma
Series A in 2020
DTx Pharma, LLC is a biotechnology company focused on developing and commercializing fatty acid-conjugated peptide therapeutics for patients with rare and chronic diseases. The company specializes in RNA-based therapeutics, utilizing a delivery technology platform that enhances the distribution of nucleic acid drugs to various tissues and organ systems beyond the liver. This innovative approach addresses limitations associated with previous-generation RNA delivery methods, such as poor pharmacokinetics and inadequate cellular uptake. DTx Pharma's products target conditions including retinitis pigmentosa, Duchenne muscular dystrophy, and central nervous system disorders. Founded in 2017 and based in San Diego, California, DTx Pharma aims to provide personalized treatment options across multiple therapeutic areas.
Avidity Biosciences
Series C in 2019
Avidity Biosciences, Inc. is a biotechnology company focused on developing oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These innovative therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. This approach allows Avidity to target previously undruggable tissue and cell types, thereby addressing the underlying genetic drivers of various diseases. The company's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, a rare muscle disease. Additionally, Avidity is advancing multiple programs aimed at treating muscle-related conditions such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Founded in 2012 and based in La Jolla, California, Avidity is also exploring therapeutic applications in immune and other cell types.
Avidity Biosciences
Venture Round in 2019
Avidity Biosciences, Inc. is a biotechnology company focused on developing oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These innovative therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. This approach allows Avidity to target previously undruggable tissue and cell types, thereby addressing the underlying genetic drivers of various diseases. The company's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, a rare muscle disease. Additionally, Avidity is advancing multiple programs aimed at treating muscle-related conditions such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Founded in 2012 and based in La Jolla, California, Avidity is also exploring therapeutic applications in immune and other cell types.
Loxo Oncology
Acquisition in 2019
Loxo Oncology, Inc. is a biopharmaceutical company based in Stamford, Connecticut, focused on developing and commercializing targeted therapies for genetically defined cancers in the United States. Founded in 2013, the company aims to bring innovative cancer treatments to the clinic by identifying actionable "driver mutations" in tumors. Its lead product candidate, larotrectinib, is an oral selective inhibitor of tropomyosin receptor kinase (TRK) and is undergoing various clinical trials for multiple cancer types, including lung, melanoma, and breast cancer. Loxo Oncology is also advancing several preclinical programs, including candidates targeting RET fusion proteins and FGFR isoforms. The company has established collaborations with several organizations to enhance its drug discovery efforts and optimize its clinical development strategies. As a subsidiary of Eli Lilly and Company, Loxo Oncology is dedicated to creating effective therapies that address specific genetic vulnerabilities in cancer patients.
Dicerna Pharmaceuticals
Post in 2018
Dicerna Pharmaceuticals is a biotechnology company dedicated to the discovery and development of innovative treatments for rare inherited diseases and other conditions affecting the liver. Utilizing its proprietary ribonucleic acid interference (RNAi) technology, specifically the GalXC platform, Dicerna focuses on silencing disease-causing genes to develop pharmaceuticals for various therapeutic areas, including liver diseases, cardiovascular diseases, and cancers. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and additional programs targeting undisclosed rare liver diseases. The company has established strategic collaborations with several major pharmaceutical firms to enhance its research and development efforts. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna Pharmaceuticals aims to address significant unmet medical needs through its innovative approaches.
Rimidi
Series A in 2018
Rimidi Inc. is a healthcare technology company based in Atlanta, Georgia, focused on improving diabetes management for patients and healthcare providers. Founded in 2011, the company offers a cloud-based software solution known as DIABETES+ME, which integrates patient-generated health data from connected devices with clinical data to provide personalized insights. This platform allows patients and physicians to identify gaps in diabetes management and outlines the necessary steps to address these gaps, ultimately helping to meet patient health targets and enhance the care cycle. By facilitating remote monitoring and enabling clinicians to make timely adjustments in treatment, Rimidi aims to address one of healthcare's most pressing challenges: diabetes.
Entrega Bio
Venture Round in 2017
Entrega Bio is a Boston-based company that specializes in developing a proprietary hydrogel technology aimed at improving the oral delivery of injectable substances, including biologics, vaccines, and other medications that typically face absorption challenges. This innovative platform allows for the creation of customizable oral dosage forms that enhance the stability and absorption of large and unstable drug molecules by effectively controlling the gastrointestinal fluid microenvironment. By collaborating with both pharmaceutical and non-pharmaceutical partners, Entrega Bio aims to advance therapeutic and diagnostic applications across various fields, including disease management and mobile health.
CoLucid Pharmaceuticals
Acquisition in 2017
CoLucid Pharmaceuticals, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, established in 2005. The company specializes in developing therapies for central nervous system disorders. Its primary product, COL-144, is an anti-migraine agent aimed at treating migraine headaches. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform designed to create novel therapeutic entities for various conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Through its innovative approaches, CoLucid Pharmaceuticals aims to address significant unmet medical needs in the field of neurology.
ApoGen Biotechnologies
Series A in 2016
ApoGen Biotechnologies, Inc., founded in 2014 and located in Seattle, Washington, is dedicated to developing innovative therapeutics aimed at addressing the challenges of cancer treatment, particularly the issue of drug resistance. The company focuses on targeting the key drivers of genomic mutations in cancer cells, which are central to tumor evolution and the development of resistance to existing therapies. By addressing the chronic mutations in cancer genomes, ApoGen aims to improve treatment efficacy, reduce cancer recurrence and metastasis, and enhance overall patient survival. The company's approach represents a shift from traditional therapies, providing new hope in the ongoing battle against cancer.
Lodo Therapeutics
Series A in 2016
Lodo Therapeutics Corporation is a drug discovery and development company dedicated to creating novel therapeutics derived from natural sources. It focuses on addressing significant health challenges, particularly resistant infectious diseases and cancers, by collaborating with global pharmaceutical companies and leading non-governmental organizations. Founded to realize the scientific vision of Dr. Sean Brady from Rockefeller University, Lodo Therapeutics utilizes a genome-based, culture-independent platform to discover and characterize small molecules sourced from environmental microbial DNA. This innovative approach leverages advancements in DNA sequencing and bioinformatics to explore the untapped potential of microbial evolution, aiming to identify therapeutically valuable pharmaceutical products. Headquartered in New York City at the Alexandria Center for Life Science, Lodo Therapeutics is committed to harnessing the power of nature in the fight against undruggable targets and high unmet medical needs.
Zymeworks
Series A in 2016
Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, focused on the discovery, development, and commercialization of innovative biotherapeutics for cancer treatment. The company's lead candidates include ZW25, a bispecific antibody undergoing Phase I and II clinical trials for various tumors, including biliary tract and gastroesophageal adenocarcinomas, and ZW49, a bispecific antibody-drug conjugate in Phase I trials for advanced HER2-expressing cancers. Zymeworks employs a computational biotechnology approach, utilizing proprietary molecular modeling and simulation technologies to optimize therapeutic antibodies and other protein-based therapeutics. The company has established strategic partnerships with notable organizations such as Merck, Eli Lilly, and Bristol-Myers Squibb, as well as collaborations aimed at advancing antibody discovery and development. Founded in 2003, Zymeworks is dedicated to addressing unmet medical needs through its advanced therapeutic platforms and integrated drug development capabilities.
Petra Pharma
Series A in 2016
Petra Pharma Corporation is a clinical-stage pharmaceutical company based in New York that focuses on discovering and developing therapies targeting phosphoinositide (PI) signaling pathways. Established in 2015, the company aims to create novel small molecules that address serious medical conditions, particularly cancer and metabolic diseases. By honing in on unique enzyme targets involved in critical cellular processes such as cell division, growth, trafficking, and signaling, Petra Pharma seeks to develop innovative treatments that can enhance human health and provide new options for healthcare providers.
Caldan Therapeutics
Series A in 2015
Caldan Therapeutics Ltd is a biotechnology company that originated as a spinout from the University of Glasgow and the University of Southern Denmark. The company focuses on the development of novel therapeutics that target free fatty acid receptors, which play a significant role in the pathophysiology of metabolic diseases, particularly Type 2 Diabetes (T2D). Through a collaboration between Professor Graeme Milligan and Professor Trond Ulven, Caldan Therapeutics aims to address various aspects of T2D, including insulin secretion, insulin sensitivity, and islet cell protection. In addition to T2D, there is potential for the company's therapeutics to be applied in treating other conditions such as non-alcoholic steatohepatitis and inflammatory diseases.
Immunocore
Series A in 2015
Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with a focus on discovering and developing novel therapeutics for cancer, viral diseases, and autoimmune conditions. The company specializes in T cell receptor (TCR) technology, which allows it to create innovative bispecific immunotherapies. Its lead product candidate, IMCgp100, is currently undergoing clinical trials for the treatment of metastatic melanoma. Immunocore's proprietary platform enables efficient manufacturing of TCR-based drugs, addressing significant unmet medical needs. Founded in 1999 and previously known as Avidex Limited, Immunocore has expanded its operations with an additional office in Conshohocken.
Zymeworks
Venture Round in 2014
Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, focused on the discovery, development, and commercialization of innovative biotherapeutics for cancer treatment. The company's lead candidates include ZW25, a bispecific antibody undergoing Phase I and II clinical trials for various tumors, including biliary tract and gastroesophageal adenocarcinomas, and ZW49, a bispecific antibody-drug conjugate in Phase I trials for advanced HER2-expressing cancers. Zymeworks employs a computational biotechnology approach, utilizing proprietary molecular modeling and simulation technologies to optimize therapeutic antibodies and other protein-based therapeutics. The company has established strategic partnerships with notable organizations such as Merck, Eli Lilly, and Bristol-Myers Squibb, as well as collaborations aimed at advancing antibody discovery and development. Founded in 2003, Zymeworks is dedicated to addressing unmet medical needs through its advanced therapeutic platforms and integrated drug development capabilities.
Sutro Biopharma
Series D in 2013
Sutro Biopharma is a clinical-stage drug discovery, development, and manufacturing company based in South San Francisco, California. The company specializes in creating next-generation protein therapeutics aimed at treating cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Among its product candidates are STRO-001, an antibody-drug conjugate targeting CD74 for patients with multiple myeloma and non-Hodgkin lymphoma, and STRO-002, which is directed against folate receptor-alpha for individuals with ovarian and endometrial cancers. Sutro Biopharma also has a collaboration and licensing agreement with Celgene Corporation to develop bispecific antibodies and antibody-drug conjugates primarily in the field of immuno-oncology. Founded in 2003, the company continues to advance its innovative therapeutic candidates through rigorous clinical development.
Novast
Corporate Round in 2012
Novast Holdings Ltd. is a multinational pharmaceutical company with operations in China and the United States, specializing in the research, development, and manufacture of FDA-inspected generic drugs. The company focuses on creating complex formulations that incorporate challenging active pharmaceutical ingredients (APIs) and offers product development services leveraging its expertise in novel technologies and drug delivery systems. Novast has established itself as a prominent player in the pharmaceutical industry in China, possessing unique capabilities in drug development, quality systems, and infrastructure. It collaborates with pharmaceutical and biotechnology companies to bring products to regulated markets, particularly the U.S. market, where it is recognized as a pioneer among Chinese companies selling pharmaceuticals locally. Novast also operates cGMP manufacturing facilities and has a management team experienced in securing numerous generic drug patents in the U.S., alongside independent research and development of innovative drug-delivery technologies.
Avid Radiopharmaceuticals
Acquisition in 2010
Avid Radiopharmaceuticals is a biopharmaceutical company based in Philadelphia, PA, focused on developing molecular imaging agents designed to improve the medical management of chronic diseases. The company aims to create innovative imaging compounds that can detect and monitor the early stages of pathological changes, facilitating earlier diagnoses and enhancing the management of treatment options. One of their key products, Amyvid, serves as an imaging tool for positron emission tomography, specifically targeting the detection of beta-amyloid plaques in the brain, which is crucial for understanding conditions like Alzheimer's disease. Avid's mission underscores their commitment to transforming disease management through advanced imaging technologies.
MacroGenics
Series D in 2008
MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, specializing in the discovery and development of antibody-based therapeutics for cancer treatment. Founded in 2000, the company focuses on immuno-oncology and has a diverse pipeline of product candidates. Key developments include Margetuximab, a monoclonal antibody in Phase III clinical trials targeting HER2-expressing tumors, and Flotetuzumab, a DART molecule aimed at treating acute myeloid leukemia. Other investigational products include MGA012, MGD013, MGD019, and Enoblituzumab, which target various immune checkpoints and tumor-associated antigens. MacroGenics is also advancing combination therapies and antibody-drug conjugates, such as MGC018, which targets solid tumors expressing B7-H3. The company has formed strategic collaborations with notable partners, enhancing its research and development efforts in the biopharmaceutical landscape.
ImClone Systems
Acquisition in 2008
ImClone Systems is a leader in the development and manufacture of therapeutic antibodies, focused on advancing oncology care through targeted biologic treatments for various cancers. Established in 1984, the company has cultivated a strong expertise in oncology and utilizes advancements in molecular biology, genomics, and antibody engineering to create a unique pipeline of product candidates aimed at specific genetic mechanisms involved in cancer progression. Besides its marketed product ERBITUX, ImClone is advancing several investigational monoclonal antibodies through various stages of clinical development, targeting major solid tumor types. Following its acquisition by Eli Lilly and Company in 2008, the company has enhanced its antibody pipeline by leveraging Lilly's global resources. ImClone's capabilities are further strengthened by its state-of-the-art, FDA-approved manufacturing facilities in Branchburg, New Jersey, which provide significant capacity for biologic production. The company's research headquarters are located in New York City, and it maintains international operations in Europe, emphasizing its commitment to addressing the medical needs of cancer patients worldwide.
SGX Pharmaceuticals
Acquisition in 2008
As of August 20, 2008, SGX Pharmaceuticals, Inc. was acquired by Eli Lilly & Co. SGX Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of therapeutics for addressing unmet medical needs in oncology. The company's product pipeline includes drug candidates from its FAST drug discovery platform, which uses X-ray crystallography and complementary biophysical and biochemical methods, combined with medicinal and computational chemistry. Its drug development programs target the c-MET receptor tyrosine kinase (MET), an enzyme implicated in an array of cancers; and the BCR-ABL tyrosine kinase enzyme for the treatment of chronic myelogenous leukemia (CML), a bone marrow cancer. Under the MET development program, the company develops SGX523, which is in Phase I clinical development studies for solid tumor indications; and SGX126, a preclinical development product for solid tumors indications. Under the BCR-ABL Development Program, SGX Pharmaceuticals develops SGX393, an oral therapy for the second-line treatment of CML, which is in preclinical development studies. Its drug discovery technologies are also applied to a portfolio of oncology targets, including JAK2, a non-receptor tyrosine kinase involved in cytokine-induced signaling and growth regulation, survival, and differentiation of cells; RAS, a protein that regulates cell growth; and three other tyrosine kinases. The company has a license and collaboration agreement with Novartis Institutes for Biomedical Research, Inc., Cystic Fibrosis Foundation Therapeutics, Inc., National Institutes of Health, and Eli Lilly & Company. SGX Pharmaceuticals, formerly known as Structural GenomiX, Inc., was founded in 1998 and is headquartered in San Diego, California.
Hypnion
Acquisition in 2007
Hypnion is a neuroscience drug discovery and development company that specializes in creating innovative therapeutics for central nervous system disorders, particularly focusing on sleep and wake-alertness issues as well as circadian rhythm abnormalities. Founded in 2000 and based in Worcester, Massachusetts, Hypnion has developed a proprietary drug discovery platform known as SCORE-2004, which measures the effects of various drugs on sleep and wake parameters. The company has attracted attention in the pharmaceutical industry, culminating in its acquisition by Eli Lilly and Company.
ICOS Corporation
Acquisition in 2007
ICOS Corporation is a biotechnology company that engages in the discovery, development, and commercialization of therapeutic products. It is engaged in the commercialization of treatments for unmet medical conditions, such as benign prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. It is the developer of a treatment known as Cialis (tadalafil), a product for the treatment of erectile dysfunction through its joint venture with Eli Lilly and Company in North America and Europe. It is also engaged in contract manufacturing services for third parties. It is in a strategic alliance with Solvay Pharmaceuticals, Inc. ICOS Corporation was established in 1989, based in Bothell, Washington. It is currently operated by Eli Lilly and Company.
Serenex
Venture Round in 2004
Serenex is a U.S.-based medical drug discovery and development company that specializes in oncology and related therapeutic areas. Founded in 2000 and acquired by Pfizer in 2008, Serenex has developed a proprietary Hsp90 product platform that includes a range of small molecule Hsp90 inhibitors targeting cancer, inflammatory diseases, fungal infections, viral diseases, and neurodegenerative conditions such as Alzheimer's. Additionally, the company is advancing SNX-1012, a treatment aimed at alleviating oral mucositis in patients with solid tumors. Through its innovative approach to drug development, Serenex aims to address significant unmet medical needs in various disease areas.
Eyetel Imaging
Series B in 2004
EyeTel Imaging, founded in 1996, specializes in developing imaging technologies aimed at addressing vision loss caused by undetected diabetic retinopathy. The company signed a license agreement with Johns Hopkins University to commercialize new retinal imaging technology, leading to the creation of the EyeTel Retinal Imaging System, which is based on the DigiScope, a semi-automated fundus camera. This system enables the detection of various ocular conditions, including age-related macular degeneration and glaucoma. EyeTel also operates the EyeTel Reading Center, a telemedicine service that offers expert analysis of patient images. Collaborating with the Wilmer Eye Institute, EyeTel has ensured extensive clinical validation of its products. The company has established manufacturing partnerships to produce the DigiScope cost-effectively, and its enhancements have made the system a reliable diagnostic tool for optometrists.
Applied Molecular Evolution
Acquisition in 2003
Applied Molecular Evolution, Inc. discovers, optimizes, and develops human bio-therapeutics. Applied Molecular Evolution offers AMEsystem technology platform for the development of human biotherapeutic candidates.
Perlegen Sciences
Series C in 2003
Perlegen Sciences engages in the discovery and commercialization of genetic variations that provide physicians with information to improve the clinical decision-making process and patient treatment outcomes. Its products include MammaPLUS, a breast cancer risk stratifier and a panel of common genetic variants that stratifies individual genetic and background/clinical risk for those at moderately elevated risk for non-familial breast cancer, as well as impacts the risk for developing invasive breast cancer; and Genotype Browser Website that provides a way to access and view the results of a study of genetic variation in various diverse human populations. Perlegen Sciences, Inc. was founded in 2000 and is based in Mountain View, California.
Pharmaserve-Lilly S.A.C.I
Acquisition in 1994
Pharmaserve-Lilly S.A.C.I provides researches, distributes, and commercializes pharmaceutical products in Greece.
Heart Rhythm Technologies
Acquisition in 1992
Heart Rhythm Technologies, Inc offers health care services including cardiovascular services.
Pacific Biotech
Acquisition in 1990
Pacific Biotech develops and markets diagnostic tests for detection of pregnancy, infectious diseases, strep throat, and mononucleosis.
Hybritech
Acquisition in 1985
Hybritech is a San Diego-based medical research company develops and markets monoclonal antibodies which are used in making diagnostic and medical monitoring tests to identify a variety of infectious, viral, and cancer-related diseases including colon and prostate cancer, infertility, allergies, and pregnancy.
Advanced Cardiovascular Systems
Acquisition in 1984
Advanced Cardiovascular Systems, Inc. develops and manufactures cardiovascular medical products. It operates as a subsidiary of Abbott Laboratories. Its medical devices help patients with heart diseases in returning to active and productive lives and physicians for improving patient management and clinical outcomes. Advanced Cardiovascular Systems, Inc. is based in Santa Clara, California. it is currently known as Abbott Cardiovascular Systems.
Therini Bio
Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies aimed at treating inflammatory neurological and retinal diseases. The company leverages insights from research that highlights the role of fibrin in driving chronic innate immune activation, which is implicated in various human diseases with significant unmet medical needs. Currently, Therini Bio is working on therapeutics that aim to protect the nervous system from damage associated with conditions such as multiple sclerosis. By developing specialized antibodies for neuroinflammatory diseases linked to vascular dysfunction, the company seeks to provide healthcare providers with effective treatment options that can improve patient outcomes.
SiteOne Therapeutics
SiteOne Therapeutics is a San Francisco-based company focused on developing innovative therapeutics and diagnostics for the treatment of acute and chronic pain. The company aims to address the limitations of existing pain management therapies, such as non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, by creating safer and more effective alternatives. Their lead candidates are highly selective inhibitors of the voltage-gated sodium ion channel Naᵥ1.7, which is crucial in the generation and conduction of pain signals. By targeting this channel, SiteOne Therapeutics seeks to provide healthcare professionals with advanced treatment options for neuropathic pain, ultimately improving patient outcomes and efficiency in pain management.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.